New Products

NEW YORK — Vidal Sassoon has developed the new Vidal Sassoon Pro Series line of hair brushes to help women achieve any hair style they desire with less fuss.

The new line includes: 
 
VSP1111, VSP1112 — Carbon+Keratin brush collection

NEENAH, Wis. — GoodNites, a Kimberly-Clark brand, is helping bed-wetting kids feel confident overnight with a new design that fits more like real underwear.

CROMWELL, Conn. — i-Health on Monday unveiled its Estroven Weight Management, a supplement specifically formulated to address the physical changes of menopause plus deliver on a core benefit of helping peri/menopausal women manage their weight as they go through this stage of life.

EL SEGUNDO, Calif. — Murad has announced the debut of Pore Reform, a skin care regimen that includes a Blackhead & Pore Clearing Duo to unclog and seal pores, shielding the skin from blackhead-causing dirt and debris.

Featuring Oxidation Reversal Complex, proprietary technology that helps reverse and prevent sebum oxidation, Blackhead & Pore Clearing Duo is clinically proven to reduce the formation of blackheads by an average of 58%, the company stated.

HOLZKIRCHEN, Germany — Sandoz has started a late-stage clinical trial of a biosimilar version of a drug used to treat autoimmune disorders, hoping the results will support its efforts to win regulatory approval in the United States and Europe.

Sandoz, the generics arm of Swiss drug maker Novartis, said it had started a phase-3 trial of biosimilar etanercept, a knock-off version of Amgen's Enbrel, used to treat chronic plaque-type psoriasis.

NEW YORK — The Food and Drug Administration has approved a gel formulation of a foot fungus drug made by Merz Pharmaceuticals, according to published reports.

According to reports, the FDA approved a gel formulation of Merz's Naftin (naftifine), used to treat athlete's foot, known medically as tinea pedis.

A cream version of the drug is already approved, and the latest approval was based on two clinical trials of more than 1,700 patients, according to reports.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating epilepsy, the company said.

The Indian generic drug maker announced the launch of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths. The drug is being distributed in bottle sizes of 30.

Lamotrigine extended-release tablets are a generic version of GlaxoSmithKline's Lamictal XR, branded and generic versions of which had sales of $300.5 million during the 12-month period that ended in April, according to IMS Health.

NEW YORK — Rally Labs recently introduced its Blowfish for Hangovers, a morning-after remedy that has a bit of a cult following in New York, into the drug channel the company noted. 

The Blowfish formulation contains a combination of aspirin and caffeine in an effervescent tablet specifically formulated for hangovers. The buffered formula helps rehydrate, restore alertness and provide relief for a headache, Rally Labs noted.